Literature DB >> 19568284

End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion.

Maurizio Bifulco, Simona Pisanti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19568284     DOI： 10.1038/nrd2775-c1

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  6 in total

1.  Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1).

Authors:  F J Barrero; I Ampuero; B Morales; F Vives; J de Dios Luna Del Castillo; J Hoenicka; J García Yébenes
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

2.  End of the line for cannabinoid receptor 1 as an anti-obesity target?

Authors:  Dan Jones
Journal:  Nat Rev Drug Discov       Date:  2008-12       Impact factor: 84.694

3.  Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy.

Authors:  Simona Pisanti; Cristina Borselli; Olimpia Oliviero; Chiara Laezza; Patrizia Gazzerro; Maurizio Bifulco
Journal:  J Cell Physiol       Date:  2007-05       Impact factor: 6.384

Review 4.  Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.

Authors:  Maurizio Bifulco; Claudia Grimaldi; Patrizia Gazzerro; Simona Pisanti; Antonietta Santoro
Journal:  Mol Pharmacol       Date:  2007-02-27       Impact factor: 4.436

Review 5.  Endocannabinoids in endocrine and related tumours.

Authors:  Maurizio Bifulco; Anna Maria Malfitano; Simona Pisanti; Chiara Laezza
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

Review 6.  Overweight, obesity, and cancer risk.

Authors:  France Bianchini; Rudolf Kaaks; Harri Vainio
Journal:  Lancet Oncol       Date:  2002-09       Impact factor: 41.316
  6 in total
  3 in total

1.  Obesity, a health burden of a global nature.

Authors:  Zhi-yun Zhang; Ming-wei Wang
Journal:  Acta Pharmacol Sin       Date:  2012-02       Impact factor: 6.150

2.  A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.

Authors:  N L Cluny; V K Vemuri; A P Chambers; C L Limebeer; H Bedard; J T Wood; B Lutz; A Zimmer; L A Parker; A Makriyannis; K A Sharkey
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model.

Authors:  Partha Mukhopadhyay; Hao Pan; Mohanraj Rajesh; Sándor Bátkai; Vivek Patel; Judith Harvey-White; Bani Mukhopadhyay; György Haskó; Bin Gao; Ken Mackie; Pál Pacher
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.